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Abstract
Objective. As smoking impacts physiological path-
ways in the central nervous system, it is important
to consider the association between smoking and
fibromyalgia, a pain condition caused predomi-
nantly by central nervous system dysfunction. The
objectives were to assess the prevalence of current
smoking among treatment-seeking chronic pain
patients with (FM1) and without (FM2) a
fibromyalgia-like phenotype; test the individual and
combined influence of smoking and fibromyalgia
on pain severity and interference; and examine
depression as a mediator of these processes.
Methods. Questionnaire data from 1566 patients
evaluated for a range of conditions at an outpatient
pain clinic were used. The 2011 Survey Criteria for
Fibromyalgia were used to assess the presence of
symptoms associated with fibromyalgia.
Results. Current smoking was reported by 38.7% of
FM1 patients compared to 24.7% of FM2 patients.
FM1 smokers reported higher pain and greater
interference compared to FM1 nonsmokers, FM2
smokers, and FM2 nonsmokers. There was no
interaction between smoking and fibromyalgia. Sig-
nificant indirect effects of fibromyalgia and smoking
via greater depression were observed for pain
severity and interference.
Conclusions. Current smoking and positive fibro-
myalgia status were associated with greater pain
and impairment among chronic pain patients, pos-
sibly as a function of depression. Although FM1
smokers report the most negative clinical symptom-
atology (i.e., high pain, greater interference) smok-
ing does not appear to have a unique association
with pain or functioning in FM1 patients, rather the
effect is additive. The 38.7% smoking rate in FM1
patients is high, suggesting FM1 smokers present
a significant clinical challenge.
Key Words. Tobacco Smoking; Chronic Pain;
Fibromyalgia; Depression
Background
Chronic pain and tobacco dependence are both highly
prevalent and comorbid disorders, and interactions
between these conditions have been of increasing
empirical interest [1]. There is accumulating evidence
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that smoking rates are elevated among persons with
chronic pain [2], smoking has been identified a unique
risk factor for chronic pain [3,4], pain has been shown
to motivate smoking [5], and smokers (relative to non-
smokers) tend to report more severe pain and greater
functional impairment [6,7]. Potential mechanisms
underlying increased pain among smokers include the
direct effects of smoking on pain pathophysiology, and
indirect effects via overlap with symptoms of depression
[8–11]. The role of depression is of particular interest
because chronic pain patients who smoke tobacco
have consistently been shown to endorse greater levels
of depression when compared with their nonsmoking
counterparts [6,7]. Research has also shown that
depression moderates the relationship between smoking
and pain, suggesting that increased pain among smok-
ers is largely driven by depression [11,12]. Consistent
with these observations, a recently proposed reciprocal
model suggests that pain, smoking, and depression
may interact in the manner of a positive feedback loop,
resulting in greater pain and the maintenance of
tobacco dependence [1].
Despite growing scientific interest in pain-smoking rela-
tions, surprisingly little is known regarding the preva-
lence and influence of smoking across different types of
chronic pain. Given evidence that nicotine exerts pro-
found effects on physiological pathways in the central
nervous system [13], researchers have begun to con-
sider the role of smoking in patients with centralized
pain (i.e., pain presumed to be caused predominantly
by central nervous system dysfunction). The most well-
studied centralized pain condition is fibromyalgia, a dis-
order characterized by chronic widespread pain,
fatigue, sleep disruptions, depressive symptoms, and
cognitive disturbances [14]. Nicotine has been shown
to influence numerous central nervous system proc-
esses associated with fibromyalgia, including the
endogenous opioid system [15,16], and serotonergic,
noradrenergic and dopaminergic neurotransmitter sys-
tems [17,18]. One possibility is that smoking interacts
with these central mechanisms, leading to worse pain
outcomes in patients with fibromyalgia compared to
patients who do not have fibromyalgia. A second, alter-
nate possibility is that smoking has a similar associa-
tion with pain regardless of whether a patient has
fibromyalgia. That is, the negative pain outcomes asso-
ciated with smoking in fibromyalgia patients may be a
function of the combination of fibromyalgia and smok-
ing. Distinguishing these possibilities is important both
for understanding the potential mechanisms by which
smoking influences pain and for informing effective
treatment protocols when dealing with pain patients
who also smoke.
The role of smoking in fibromyalgia is understudied rela-
tive to other types of chronic pain (e.g., low back pain
and rheumatoid arthritis [3,4]). We are aware of only
three studies that examined associations between
smoking and fibromyalgia [19–21], and despite yielding
initial evidence that smoking may be related to greater
fibromyalgia-related pain and impairment, these studies
were limited to within-group analyses (i.e., failed to
include nonfibromyalgia comparisons) among relatively
small samples of smokers (Ns533, 145, and 51,
respectively), and failed to account for the role of
depression as a potential mechanistic factor. The cur-
rent lack of clarity regarding associations between pain,
current smoking, and fibromyalgia status among
treatment-seeking chronic pain patients represents a
critical barrier to progress in this domain.
The objectives of the current study were to: 1) generate
base rate data regarding the prevalence of current
smoking among a large sample of treatment-seeking
chronic pain patients with and without a fibromyalgia-
like phenotype; 2) test the individual and combined influ-
ence of current tobacco use and fibromyalgia status on
self-reported pain severity and pain interference; and 3)
examine depression as a mediator of these outcomes.
Specifically, we hypothesized that current smoking and
positive fibromyalgia status would each be independ-
ently associated with greater self-reported pain severity
and functional interference among persons with chronic
pain, even after accounting for relevant socio-
demographic factors. We further hypothesized that
symptoms of depression would mediate associations
between smoking/fibromyalgia status and pain severity/
interference.
Materials and Methods
Participants
Participants included 1,566 noncancer chronic pain
patients who sought treatment at a university-based
outpatient pain medicine clinic between November 2010
and June 2012. As part of an ongoing clinical care and
research initiative, all new patients were mailed a packet
of questionnaires to complete prior to their initial visit.
Consistent with IRB approval obtained prior to the start
of this initiative, informed consent was waived, and
questionnaire data was entered into the Assessment of
Pain Outcomes Longitudinal Electronic Data Capture
(APOLO EDC) system [22]. Although a total of 1,903
patients completed the questionnaires, 337 were
excluded due to missing data on smoking status and/or
the fibromyalgia scale. There were no other exclusion
criteria.
Participants in this study were being evaluated for a
range of primary diagnostic conditions, including chronic
back pain (47%), musculoskeletal pain (15%), facial pain
(8%), and disorders of the central nervous system (6%),
among others. Given that a significant proportion of
treatment-seeking pain patients can be expected to fall
along a continuum of centralized pain processing dys-
function [23,24], the 2011 Survey Criteria for Fibromyal-
gia allows for the assessment of fibromyalgia in clinical
and epidemiological studies without requiring a tender
point examination [25]. The measure is not intended to
replace a clinical evaluation for the diagnosis of
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fibromyalgia, but can be used to place patients on the
continuum of fibromyalgia-like symptomatology.
Measures
Smoking Status
Smoking status was assessed via a single item that asked
participants to indicate whether they currently smoke ciga-
rettes (Yes5 current smoker, No5 nonsmoker). Current
smokers were further asked to indicate how many packs
of cigarettes they smoke per day (<1 pack per day, 1
but< 2 packs per day, or 2 packs per day), and for
how many years they have been smoking.
Fibromyalgia Status
The 2011 Survey Criteria for Fibromyalgia were used to
assess the presence of symptoms associated with fibro-
myalgia. Although a definitive diagnosis of fibromyalgia
cannot be made with survey criteria alone, the 2011 crite-
ria are considered a reliable measure for classifying
patients in survey research without the need for a physical
exam [26]. The fibromyalgia survey criteria include the
Widespread Pain Index (WPI) and Symptom Severity (SS)
scale. The WPI was calculated using the Michigan Body
Map [27], a one-sided body image with check boxes for
35 body areas, including the 19 body areas relevant to
the WPI (scored 0–19). The SS scale was calculated by
summing responses to six items (scored 0–12), that
assessed: past-week fatigue, trouble thinking or remem-
bering, and waking up tired (rated from 05 no problem to
35 severe); and the presence of pain or cramps in the
lower abdomen, depression, and headache over the past
6 months (rated 15 yes, 05 no). The fibromyalgia survey
allows for a clinical cut point for being termed
“fibromyalgia-positive” (FM1). Patients were considered
FM1 if they scored either 7 on the WPI and 5 on the
SS scale, or between 3 and 6 on WPI and 9 on the SS
[28]. Patients who did not meet these criteria were consid-
ered negative for fibromyalgia (FM2) [28]. Using a cutoff
score to classify patients as FM1 or FM2 aids interpreta-
tion of data and is also more likely to be clinically
meaningful.
Pain Assessment
The pain assessment consisted of the Brief Pain Inven-
tory (BPI). The BPI assesses both the severity of pain
and its interference on common activities [29]. Pain
severity on average, over the last week, and right now
was rated on a scale of 0 (No Pain) to 10 (Pain as bad
as you can imagine), and averaged to generate a single
composite score (a5 0.88). The extent to which pain
interfered with activity, mood, walking, work, relations
with others, sleep, and enjoyment over the past week
was rated on a scale of 0 (Does not interfere) to 10
(Completely interferes), and averaged to generate a
single composite score (a5 0.89).
Symptoms of Depression
Symptoms of depression were assessed using the 7-
item depression subscale from the Hospital Anxiety and
Depression Scale (HADS) [30]. The HADS is a brief and
widely used instrument to measure psychological dis-
tress in both general and medical populations [31]. It
has been used in musculoskeletal populations [32], as
well as in patients with chronic fatigue [33] and fibro-
myalgia [34]. A score of 0–7 is considered within the
normal range; a score of 8–10 is suggestive of the pres-
ence of depression; and a score of 11 or higher indi-
cates a high probability that depression is present [35].
Statistical Analyses
Data analyses for the entire sample included computing
descriptive statistics for demographic variables (age,
sex, race, education) and criterion variables (pain sever-
ity, pain interference, and depression) according to FM
group and smoking status. Criterion variables were also
tested for normality using Q-Q plots. Group differences
were tested by performing analysis of variance (ANOVA)
for the continuous demographic (significance5P< 0.01
to correct for multiple comparisons), and chi-square
tests for the categorical demographic variables.
To evaluate the effects of smoking and FM status on
pain severity and pain interference two analysis of
covariance (ANCOVA) models were conducted. The
main effects of smoking and FM status were included in
the models along with the interaction of smoking with
FM status to predict pain severity and pain interference.
Demographic variables (sex, age, race, education) were
included in each model as covariates. Additionally,
planned comparisons assessing differences in pain
interference and pain severity between smoking FM1
patients and all other patients were conducted. Bonfer-
roni adjusted P -values were utilized and reported for
each planned comparison.
Next, to examine the potential indirect effect of smoking/
FM status on pain via depression, separate path analysis
models were conducted (see results). Demographic vari-
ables (sex, age, race, education) were included as covari-
ates in each model. Full information maximum likelihood
was used to account for missing data [30], and boot-
strapped standard errors were utilized. Mediation was
assessed using the product of the coefficients method
[36]. All statistical analyses were conducted using Stata
13.1 (StataCorp, College Station, TX, USA).
Results
Prevalence of Fibromyalgia-Like Phenotype and
Current Smoking
Across the entire sample (N5 1,566), 35.2% of chronic
pain patients were determined to be FM1 and 29.6%
endorsed current tobacco smoking. Frequencies or
means and standard deviations for demographic
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variables based on fibromyalgia and smoking status are
presented in Table 1. FM1 patients were more likely to
be younger, female, non-White, and to not have grad-
uated college compared to FM2 patients. Similarly,
compared to non-smokers, current smokers were more
likely to be younger and to not have graduated college.
Prevalence of Current Smoking by Fibromyalgia Status
The rate of current smoking was significantly higher
among FM1 patients (39%), relative to FM2 patients
(25%; v25 33.23, P< 0.001). There was no difference
between FM1 smokers (M50.90, SD50.48) and FM2
smokers (M50.90, SD5 0.47) with regard to average
number of daily cigarette packs smoked [t(424)50.04,
P50.97]. Further, there was no difference in number of
years smoking between FM1 (M5 21.32, SD5 0.83)
and FM2 smokers (M5 22.29, SD5 0.78)
[t(398)5 0.85, P5 0.39].
Associations Between Fibromyalgia/Current Smoking
Status and Pain Severity/Interference
Unadjusted mean scores for the criterion variables
within each FM group broken down by smoking status
are reported in Table 2. The estimated marginal means
of the ANCOVA models predicting pain severity and
interference are presented in Figures 1 and 2. There
were main effects of both FM status [F(1,
1420)5 60.51, P< 0.001] and smoking status [F(1,
1420)5 37.80, P<0.001] on pain severity, such that
current smokers and FM1 patients reported more
severe pain than did current nonsmokers and FM-
patients. Further, there were main effects of both FM
status [F(1, 1406)5 131.56, P< 0.001] and smoking
status [F(1, 1406)5 28.87, P< 0.001] on pain interfer-
ence, such that current smokers and FM1 patients
reported more pain interference. As seen in Figures 1
and 2, we observed no interaction between FM or
smoking status for either pain interference [F(1,
1406)5 0.46, P50.50] or pain severity [F(1,
1420)5 0.77, P50.38]. Planned comparisons further
revealed that pain ratings were highest for FM1 smok-
ers, relative to FM1 nonsmokers (Mean differ-
ence5 0.56, SE50.16, Bonferroni adjusted P50.003),
FM2 smokers (Mean difference5 0.72, SE5 0.17, Bon-
ferroni adjusted P<0.001), and FM2 nonsmokers
(Mean difference5 1.46, SE5 0.15, Bonferroni adjusted
P< 0.001). Similarly, interference ratings were highest
for FM1 smokers, relative to FM1 nonsmokers (Mean
difference5 0.60, SE5 0.19, Bonferroni adjusted
Table 1 Descriptive statistics for demographic, pain, and mood variables by fibromyalgia and smoking
status
Fibromyalgia Status Smoking Status
Variable
Full Sample
(N5 1,566)
FM1
(n5 551)
FM –
(n5 1,015) P
Current Smoker
(n5 464)
Nonsmoker
(n5 1,102) P
Age 49.36 15.4 46.66 13.3 50.86 16.2 <0.001 43.96 11.9 51.66 16.1 <0.001
Sex (% female) 59.3 66.4 55.5 <0.001 58.6 59.6 0.71
Ethnicity (% white) 89.4 87.1 90.6 0.03 89.3 89.4 0.95
Education
(% college graduate)
34.6 29.9 38.1 0.001 22.1 40.8 < 0.001
Marital status (% married) 55.9 50.9 58.7 0.003 43.1 61.4 <0.001
Employment status
(% employed)
36.4 27.3 41.3 <0.001 29.2 39.4 <0.001
Past smoking
(% former smokers)
43.9 43.6 44.1 0.890 – 43.9 –
Duration of smoking
(# of years)
21.8611.4 21.3611.2 22.3611.6 0.394 21.8611.4 – –
Pain duration
(% longer than 1 yr)
70.7 79.1 66.4 <0.001 75.1 68.9 0.048
Pain severity
(range50–10)
6.366 1.87 7.056 1.54 5.996 1.92 <0.001 7.026 1.62 6.086 1.89 <0.001
Pain Interference
(range50–10)
6.856 2.24 7.916 1.71 6.276 2.28 <0.001 7.576 1.88 6.546 2.30 <0.001
Depression
(range50–21)
8.916 4.60 11.136 4.32 7.706 4.29 <0.001 10.606 4.66 8.206 4.39 <0.001
Note: Values are the mean, SD unless otherwise indicated. FM15meets ACR survey criteria for fibromyalgia; FM25 does not
meet ACR survey criteria for fibromyalgia. Ns may vary due to missing data on the demographic and criterion variables.
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P50.01), FM2 smokers (Mean difference5 1.3,
SE50.20, Bonferroni adjusted P< 0.001), and FM2
nonsmokers (Mean difference5 2.09, SE5 0.17, Bon-
ferroni adjusted P<0.001).
Depression as a Mediator of Associations Between
Fibromyalgia/Current Smoking Status and Pain
Severity/Interference
To determine the explanatory relevance of depression
with regard to observed relations between fibromyalgia/
smoking status and greater pain severity/interference,
two separate path models were examined. Bootstrapping
of the standard errors with 1,000 replications was
employed in each model. Both standardized and unstan-
dardized coefficients are presented in Figure 3a and 3b.
As seen in Figures 3a and 3b, significant indirect effects
of fibromyalgia and smoking status via greater depression
were observed for both pain severity and interference
outcomes, even after accounting for relevant sociodemo-
graphic factors (i.e., gender, age, education, and race).
Indirect effects reported here are the multiplicative prod-
uct of the unstandardized coefficients from the predictor
variable (e.g., smoking) to the mediator depression, and
from the mediator to the outcome variable (e.g. pain
severity). For pain severity (Figure 3a), the indirect effect
of depression was 0.327 (P< 0.001; 95% CI: 0.243–
0.410) for fibromyalgia status, and 0.183 (P< 0.001;
95% CI: 0.119–0.247) for current smoking status. Overall,
Table 2 Pain severity, pain interference, and symptoms of depression as a function of fibromyalgia and
smoking status
FM1 Current Smoker
(n5 213)
FM1 Nonsmoker
(n5 338)
FM2 Current Smoker
(n5 251)
FM2 Nonsmoker
(n5 764)
Pain severity
(range50–10)
7.446 1.32 6.806 1.62* 6.656 1.76* 5.776 1.92*
Pain interference
(range50–10)
8.326 1.38 7.666 1.84* 6.956 2.01* 6.046 2.32*
Depression
(% scoring 11 or above)
69.19% 52.10%* 35.10%* 22.19%*
Note: Values are the unadjusted means, SD unless otherwise indicated. FM15meets ACR survey criteria for fibromyalgia;
FM25 does not meet ACR survey criteria for fibromyalgia. Pain severity and pain interference were measured using the BPI.
Symptoms of depression were assessed using the HADS. A score of 11 or higher on the HADS indicates a high probability that
depression is present. Ns may vary due to missing data on the criterion variables. * indicates that the means or percentages
were statistically significantly different from the FM1 smoker reference group at Bonferroni-adjusted P<0.05 or less.
Figure 1 Predicted means of pain interference by
FM status and smoking status.
Note: Marginal means displayed at means of other
covariates.[Color figure can be viewed in the
online issue, which is available at wileyonlineli-
brary.com.]
Figure 2 Predicted means of pain severity by FM
status and smoking status.
Note: Marginal means displayed at means of other
covariates. [Color figure can be viewed in the
online issue, which is available at wileyonlineli-
brary.com.]
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this model accounted for 20% of the variance in pain
severity and 18% of the variance in depression symp-
toms. For pain interference (Figure 3b), the indirect effect
of depression was 0.778 (P< 0.001; 95% CI: 0.649–
0.907) for fibromyalgia status, and 0.474 (P< 0.001;
95% CI: 0.347–0.601) for smoking status. Overall, this
model accounted for 38% of the variance in pain interfer-
ence, and 17% of the variance in depression symptoms.
Discussion
To our knowledge, this is the first study to demonstrate
that both current smoking and positive fibromyalgia status
may be associated with greater pain and physical impair-
ment among treatment-seeking chronic pain patients,
possibly as a function of depression. Our path analysis
models revealed significant indirect effects for current
smoking and positive fibromyalgia status on both pain
severity and pain interference, via greater scores on a
measure of depression. As hypothesized, FM1 smokers
reported more severe pain and functional impairment
than did FM1 nonsmokers. Although these results are
generally consistent with initial findings that smokers with
fibromyalgia have reported greater pain and impairment
than nonsmokers with fibromyalgia [19–21], these earlier
studies failed to include nonfibromyalgia comparisons,
thus prohibiting inferences regarding the relative impor-
tance of centralized pain in these outcomes.
To address gaps in the literature we tested a model that
included main effects and interactions between smoking
and fibromyalgia status. Both current smoking and having
met survey criteria for fibromyalgia were independently
associated with more severe pain and functional impair-
ment among our sample of treatment-seeking chronic
pain patients. As seen in Figures 1 and 2, the higher
scores on pain severity and pain interference seen in
FM1 smokers compared to FM1 nonsmokers were
equivalent to the differences seen between smokers and
nonsmokers who are FM2. Although we observed no
interaction between smoking and fibromyalgia status for
either outcome, planned comparisons revealed that FM1
smokers reported more severe pain and physical interfer-
ence than did FM1 nonsmokers, FM2 smokers, or FM2
nonsmokers. Taken together, these findings support an
additive effect of positive FM and smoking status on self-
reported pain severity and pain interference. That is, we
did not find that smoking has a unique association with
pain outcomes among patients who were FM1, as has
been hypothesized based on previous studies that did not
include an FM2 smoking group [20].
Depression has been considered as a key mechanistic
factor in complex pain-smoking relations [1,13,37], and
these findings are consistent with previous evidence
that depression may help to explain why smokers with
chronic pain tend to endorse more severe pain [11,12].
Indeed, it is possible that an underlying vulnerability
(e.g., neurobiological, behavioral, affective, cognitive) is
explanatory. For example, symptoms of depression are
more prevalent among both smokers [38,39] and per-
sons with chronic pain [40,41], often doubling rates
observed in the general population. There is also some
evidence that symptoms of depression and smoking
behavior may be reciprocal in nature [42]. The role of
depression is of particular interest because chronic pain
patients who smoke tobacco have been shown to
endorse greater levels of depression when compared
with their nonsmoking counterparts [12], and depression
has consistently been associated with more severe pain
and functional impairment [9]. Consistent with these
observations, abnormal levels of serotonin and norepi-
nephrine have been found in patients who smoke, have
depression, or experience chronic pain [34–36]
Figure 3 Path models testing mediation of FM
status and smoking status through depression
symptoms.
Note: Standardized coefficients are presented first
and unstandardized path coefficients are pre-
sented in parentheses. *** is P<0.001, ** is
P<0.01, * is P<0.05. Dashed lines denote that
paths from covariates gender, age, race, and edu-
cation were estimated for both the mediator vari-
able (depression) and outcome variables. [Color
figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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suggesting that overlapping neurobiological factors likely
influence the interaction. Medications that modulate
central serotonin (in addition to nonpharmacological
interventions such as cognitive-behavioral therapy) are
evidence-based in the treatment of smoking cessation
[43,44], depression [45,46], and fibromyalgia [47,48].
Future research should address the treatment implica-
tions of the affect-smoking–pain interaction, with partic-
ular focus on the role of depression.
Although recent data show that smoking prevalence in peo-
ple with chronic pain may be twice that of the rate observed
in the rate observed in the general population [2], little is
known about how smoking rates may vary as a function of
chronic pain type/source. These results indicated that the
prevalence of current tobacco smoking was significantly
higher among treatment-seeking chronic pain patients who
also met diagnostic criteria for fibromyalgia (39% for FM1 vs
25% for FM2). Given that some of the most appropriate
base rate information may be derived from clinical samples
[49], these data further our understanding of how endorse-
ment of centralized pain may confer increased risk for cur-
rent tobacco smoking. Although previous studies reported
smoking rates between 15% [21] and 26% [50] among
fibromyalgia patients, it is important to note that the current
data reflect rates of smoking among patients undergoing
treatment for other primary pain complaints (e.g., chronic
low back pain) who met the survey criteria for fibromyalgia
[14,51]. Thus, although these findings may be applicable to
persons who are formally diagnosed with fibromyalgia, the
current data are most generalizable to a broader chronic
pain population.
Given what is known about the health effects of smoking
and the potential for smoking to influence pain, all persons
with chronic pain should be encouraged to quit smoking.
Although there has been little research regarding the effi-
cacy of smoking cessation among persons with chronic
pain [52] and the impact of smoking cessation on pain out-
comes has yet to be established, there is evidence that
smokers with pain are motivated to quit [53]. However,
there is also some evidence that smokers in pain may
experience greater difficulty when attempting to quit [54],
and recurring pain has been prospectively linked to poor
cessation outcomes [55]. Pain has been shown to be a
potent motivator of smoking, [5] smoking may be used to
cope with pain [44,45] and there is evidence that persons
with chronic pain may smoke tobacco, in part, to distract
themselves from pain and to better manage negative affect
[56]. From a clinical perspective, the current study captured
a subgroup of smokers who may struggle to quit, and bet-
ter understanding why the smoking rate is so high in FM1
patients is important to inform smoking cessation. While
this study did not assess patient beliefs about smoking, we
hypothesize that FM1 smokers may be more likely than
FM2 smokers to report that smoking helps with affect reg-
ulation given that 69% of FM1 smokers endorsed symp-
toms suggestive of depression compared to 35% of FM2
smokers. In general, smokers report that smoking helps
with negative affect, yet smokers also report greater affec-
tive distress compared to nonsmokers [38]. This paradox
suggests that smoking is an ineffective long term coping
strategy for negative affect, yet the belief that smoking
helps regulate mood is a barrier to cessation. Understand-
ing differential motives for smoking and barriers to cessa-
tion among FM1 vs FM2 smokers would help inform the
development of tailored cessation programs.
Strengths of the current study include analysis of a large
sample of treatment-seeking chronic pain patients, inclu-
sion of both smokers and nonsmokers, application of
established criteria for fibromyalgia, and our ability to
account for relevant sociodemographic factors. Several
limitations also bear noting. First, the cross-sectional
design precludes causal inferences regarding temporal
precedence. Thus, conclusions regarding the relative
importance of fibromyalgia status above and beyond
other pain and smoking relevant factors would be prema-
ture. We were also unable to determine when patients
may have started smoking in relation to the onset of cen-
tralized pain symptoms. Second, patients were seen at
an outpatient pain clinic in the Midwest and were pre-
dominantly Caucasian, thus limiting generalizability of
these findings. Third, given that only pain over the last
week was assessed, these data cannot speak to the
potential covariation of pain and smoking behavior over
time. Future studies using prospective designs to explore
the temporal effects smoking, pain, and depression
would be informative, as would studies on tailored inter-
ventions that address pain, smoking, and depression.
In conclusion, these findings shed light onto a potential con-
cern with regards to the high smoking rate in treatment
seeking patients who in addition to their primary pain diag-
nosis present with symptoms consistent with fibromyalgia.
The smoking rate in FM1 patients was double the national
smoking rate of 19.0% and significantly higher than the
smoking rate of 20.5% in the state of Michigan [57], which
suggests a need for further investigation into the smoking
behavior in these patients. Additionally, the results of this
study contribute new information about the additive associa-
tion between smoking and fibromyalgia and provide the first
evidence indicating that the association between smoking
and clinical symptoms is similar in patients with and without
fibromyalgia. Finally, depression emerged as an important
factor in the association between smoking/fibromyalgia sta-
tus and pain outcomes. Interrelations between tobacco
smoking, depression, and chronic pain are likely complex
and highly relevant to the treatment of both pain and smok-
ing [12]. Future research should evaluate the utility of incor-
porating either pain- or smoking-relevant treatment
components into existing interventions for tobacco depend-
ence or chronic pain.
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